Introduction: Chronic myeloid leukemia (CML) may significantly affect quality of life and life expectancy in the accelerated and acute phases, especially if presented with health emergencies. Objective: The purpose of the study was the evaluation of the personalized management milestones in CML cases presented with ovarian apoplexy and the analysis of the international experience on health emergencies in this leukemia. Materials and Methods: An original, case-report study was performed. The diagnosis was confirmed by cytological, cytogenetic and molecular examinations of the peripheral blood and bone marrow at the comprehensive research cancer center— Institute of Oncology from Moldova. The real-time PCR was performed for quantitative detection of BCR-ABL gene p210 and p190 transcripts. The ECOG Scale and complete hematologic response (CR) estimated the short-term results. The ECOG performance status served as a measure of functional status. Its scores range from 0 to 5 and correlate with the level of patient functioning. CR is the disappearance of all detectable clinical and hematological signs of malignant neoplasm in response to treatment. CR span was assessed in months. The overall and relapse-free survivals asserted the long-term results of treatment, and were evaluated in months as a case. Results: CML may be manifested by life-threatening conditions, including infections and thrombotic events, splenic infarcts and ruptures, bleedings, etc. CML with the uncommon onset under the form of the ovarian apoplexy is described. The hematological CR was obtained under the treatment with imatinib mesylate. The molecular CR and the long-lasting overall survival (197.5 months) were achieved after the treatment with nilotinib. Under the treatment with tyrosine kinase inhibitors, the patient did not experience the disease burden and side effects, and resumed her work, with a good life quality (ECOG score is 0). Discussion: CML may be manifested by life-threatening health emergencies, especially thrombotic events, splenic infarcts and ruptures, bleedings, etc. The CML patients with high leukocyte and platelet counts may experience also different symptoms of hyperviscosity: tinnitus, priapism, stupor, visual abnormalities and cerebrovascular accidents. However, the management of CML with the life-threatening conditions, especially in the accelerated and acute phases, should be realized with participation of the multidisciplinary teams. Conclusions: The ovarian apoplexy may serve
References
[1]
Hughes, T.P., Ross, D.M. and Melo, J.V. (2016) Handbook of Chronic Myeloid Leukemia. Springer International Publishing, Switzerland, 1-66.
[2]
Quintas-Cardama, A. and Cortes, J.E. (2006) Chronic Myeloid Leukemia: Diagnosis and Treatment. Mayo Clinic Proceedings, 81, 973-988. https://doi.org/10.4065/81.7.973
[3]
Hehlmann, R., Hochhaus, A., Baccarani, M. (2007) Chronic Myeloid Leukaemia. The Lancet, 370, 342-350. https://doi.org/10.1016/S0140-6736(07)61165-9
[4]
Jabbour, E. and Kantarjian, H. (2018) Chronic Myeloid Leukemia: 2018 Update on Diagnosis, Therapy and Monitoring. American Journal of Hematolog, 93, 442-459. https://doi.org/10.1002/ajh.25011
[5]
Thompson, P.A., Kantarjian, H.M. and Cortes, J.E. (2015) Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015. Mayo Clinic Proceedings, 90, 1440-1454. https://doi.org/10.1016/j.mayocp.2015.08.010
[6]
Schubauer-Berigan, M.K., Daniels, R.D. Fleming, D.A., et al. (2007) Risk of Chronic Myeloid and Acute Leukemia Mortality after Exposure among Workers at Four U.S. Nuclear Weapons Facilities and a Nuclear Naval Shipyard. Radiation Research, 167, 222-232. https://doi.org/10.1667/RR0724.1
[7]
Silver, S.R., Daniels, R.D., Taulbee, T.D., et al. (2004) Differences in Mortality by Radiation Monitoring Status in an Expanded Cohort of Portsmouth Naval Shipyard Workers. Journal of Occupational and Environmental Medicine, 46, 677-690. https://doi.org/10.1097/01.jom.0000128154.79025.2a
[8]
Strom, S., Yamamura, Y., Kantarijian, H., et al. (2009) Obesity, Weight Gain, and Risk of Chronic Myeloid Leukemia. Cancer Epidemiology, Biomarkers & Prevention, 18, 1501-1506. https://doi.org/10.1158/1055-9965.EPI-09-0028
[9]
Kosmidis, P.A., Schrijvers, D., André, F. and Rottey, S. (2005) ESMO Handbook of Oncological Emergencies. Taylor & Francis Group, Oxford.
[10]
Al-Achkar, W., Moassass, F., Youssef, N. and Wafa, A. (2016) Correlation of p210 BCR-ABL Transcript Variants with Clinical, Parameters and Disease Outcome in 45 Chronic Myeloid Leukemia Patients. Journal of BUON, 21, 444-449.
[11]
Castagnetti, F., Palandri, F., Amabile, M., et al. (2009) Results of High-Dose Imatinib Mesylate in Intermediate Sokal Risk Chronic Myeloid Leukemia Patients in Early Chronic Phase: A Phase 2 Trial of the GIMEMA CML Working Party. Blood, 113, 3428-3434. https://doi.org/10.1182/blood-2007-08-103499
[12]
Efficace, F., Baccarani, M., Breccia, M., Alimena, G., Rosti, G., et al. (2011) Health-Related Quality of Life in Chronic Myeloid Leukemia Patients Receiving Long-Term Therapy with Imatinib Compared with the General Population. Blood, 118, 4554-4560. https://doi.org/10.1182/blood-2011-04-347575
[13]
ESMO Guidelines Committee. (2017) Chronic Myeloid Leukemia: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 28, IV41-IV51. https://doi.org/10.1093/annonc/mdx219
[14]
Arulkumaran, S., Koh, C.H., Pang, M., Ding, Z.P. and Ratnam, S.S. (1987) Chronic Myeloid Leukemia Presenting as a Gynecological Emergency. Gynecologic Oncology, 28, 111-115. ttps://doi.org/10.1016/S0090-8258(87)80015-X
[15]
Swerdlow, S.H., Campo, E., Harris, N.L., et al. (2017) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Edition, International Agency for Research on Cancer, Lyon.
[16]
Carbone, A. (2020) Classification of Tumors of the Hematopoietic and Lymphoid Tissues. Discovering Diseases—Defining Their Features. Bloods, 1, 7-9. https://doi.org/10.3390/bloods1010004
[17]
Dorfman, L.E., Floriani, M.A., Oliveira, T.M., et al. (2018) The Role of Cytogenetics and Molecular Biology in the Diagnosis, Treatment and Monitoring of Patients with Chronic Myeloid Leukemia. Brazilian Journal of Pathology and Laboratory Medicine, 54, 83-91. https://doi.org/10.5935/1676-2444.20180015
[18]
Saha, I. and Paul, B. (2020) Essentials of Biostatistics & Research Methodology. 3rd Edition, Academic Publishers, Kolkata, 1-398.
[19]
Rueda-Esteban, R., Muñoz, N.S., Díaz, M.B., Sierra, A.G. and Perdomo, C.F.(2019) Spontaneous Splenic Rupture in a Patient with Chronic Myeloid Leukemia: A Case Report. International Journal of Surgery Case Reports, 66, 122-125. https://doi.org/10.1016/j.ijscr.2019.11.051
[20]
Chaudhary, V., Sachdeva, P., Karantha, P. and Arora, R. (2013) Spontaneous Hemoperitoneum in Chronic Myeloid Leukemia: An Unusual Etiology. Journal of Hematology, 2, 40-41. https://doi.org/10.4021/jh73e
[21]
Valentsik, F. (1951) Profuse Ovarian Hemorrhage in Chronic Myelocytic Leukemia. Bratislavské lekárske listy, 31, 416-421.
[22]
Padmanabhan, V., Shahin, M.M. and Abdallah, K. (2017) Chronic Myeloid Leukaemia Manifesting as a Gynecological Emergency in a Young Woman. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 6, 3655-3656. https://doi.org/10.18203/2320-1770.ijrcog20173504
[23]
Joseph, D.E. and Durosinmi, M.A. (2008) Neurological Complications of Chronic myeloid Leukaemia: Any Cure? Nigerian Journal of Clinical Practice, 11, 246-249.
[24]
Abuelgasim, K.A., Alshieban, S., Almubayi, N.A., Alhejazi, A., Jazieh, A.R. (2016) An Atypical Initial Presentation of Chronic Myeloid Leukemia with Central Nervous System and Lymph Node Blast Crises. Case Reports in Oncology, 9, 415-421. https://doi.org/10.1159/000447711
[25]
Yoshizaki, N., Kohda, K., Nakazawa, O., et al. (2989) A Case of Chronic Myelogenous Leukemia Complicated with Nephrotic Syndrome. Rinsho Ketsueki, 30, 691-696.
[26]
Bee, P.C., Gan, G.G., Sangkar, V.J. and Haris, A.R. (2008) Nephrotic Syndrome in a Patient with Relapsed of Chronic Myeloid Leukemia after Peripheral Blood Stem Cell Transplantation. Medical Journal of Malaysia, 63, 71-72.
[27]
Ali, E., Soliman, A., De Sanctis, V., Nussbaumer, D. and Yassin, M. (2021) Priapism in Patients with Chronic Myeloid Leukemia (CML): A Systematic Review. Acta Biomedica, 92, 1-8.
[28]
Chang, M.W., Tang, C.C. and Chang, S.S. (2003) Priapism—A Rare Presentation in Chronic Myeloid Leukemia: Case Report and Review of the Literature. Chang Gung Medical Journal, 26, 288-292.
